Literature DB >> 15769575

Overdose of aripiprazole, a new type of antipsychotic.

Shaun D Carstairs1, Saralyn R Williams.   

Abstract

Aripiprazole is the first member of a new class of antipsychotic medications. Unlike other antipsychotics, it acts as a partial agonist at dopamine D(2) and 5-HT(1A) receptors, thereby mitigating most of the adverse reactions such as extrapyramidal side effects and hyperprolactinemia. Additionally, most research to date has suggested a low incidence of QTc prolongation and orthostatic hypotension at therapeutic doses. Experience in the setting of intentional overdose, however, is limited. We present a case of a 27-year-old woman who intentionally ingested 330 mg of aripiprazole in a suicide attempt. Clinical effects were limited to mild sedation. Serum levels performed by the drug's manufacturer confirmed a total level (parent drug and active metabolite) of 716 ng/mL, nearly six times the upper limit of accepted therapeutic levels. This suggests that aripiprazole's therapeutic index is quite high and reinforces the drug's known safety profile.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15769575     DOI: 10.1016/j.jemermed.2004.09.013

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  3 in total

Review 1.  [Psychotropic agents in emergency medicine].

Authors:  A Wolf; M J Müller; F-G B Pajonk
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-02       Impact factor: 0.840

Review 2.  A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.

Authors:  Hock Heng Tan; Jason Hoppe; Kennon Heard
Journal:  Am J Emerg Med       Date:  2009-06       Impact factor: 2.469

Review 3.  The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.

Authors:  Christoffer Polcwiartek; Benjamin Sneider; Claus Graff; David Taylor; Jonathan Meyer; Jørgen K Kanters; Jimmi Nielsen
Journal:  Psychopharmacology (Berl)       Date:  2015-08-01       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.